HT
AMLX icon

Headlands Technologies’s Amylyx Pharmaceuticals AMLX Stock Holding History

Headlands Technologies’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,814
Closed -$275K – 713
2026
Q1 		$275K Sell
19,814
-10,729
-35% -$151K 0.03% 518
2025
Q4 		$369K Buy
+30,543
New +$415K 0.03% 472

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Headlands Technologies's AMLX Position: Q2 2026 in Review

Headlands Technologies sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 19,814 shares — an estimated $275K sold.

Headlands Technologies first reported a position in AMLX in Q4 2025 and held it in 2 quarters. The position peaked at $369K in Q4 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Headlands Technologies reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 19,814 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $275K.
  • Headlands Technologies first reported a position in Amylyx Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Headlands Technologies's Amylyx Pharmaceuticals position peaked at $369K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.